Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?

8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...

Read more →

Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund

2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...

Read more →